Skip to content

The Big Deals 💣 : Resilience, H, And May Health

GenAI (of course), and MedTech get new checks.

Resilience co-founders Jonathan Benhamou and Céline Lazorthes
Resilience co-founders Jonathan Benhamou and Céline Lazorthes

What: Resilience has developed a remote monitoring platform for cancer patients.

Why: The growing rates of cancer combined with a shortage of healthcare workers have put a strain on the ability of hospitals to sufficiently track the progress of patients when they are not admitted.

Funding: $25 million
Who: Co-founders Jonathan Benhamou and Céline Lazorthes

Investors: Picus Capital and Red River West led the round, which also included money from Cathay Innovation, Singular, and Seaya Ventures.

What's Next: Resilience is currently available in France and Belgium and will use the money to expand into Germany. The startup is also developing a platform for pharmaceutical companies.

Inside Resilience’s Bid To Reinvent Cancer Care
Can AI and data transform oncology?

What: H is building foundational action models for GenAI to be deployed across business and consumer verticals.

Why: The company's focus will include AI agents, systems that help automate tasks typically performed by humans by breaking them down into different steps.

Funding: $220 million (40% equity and 60% debt convertible at later funding stages.)
Who: Co-founders are former Google DeepMind researchers Karl Tuyls (Chief Research Operations), Laurent Sifre (CTO), Julien Perolat (Chief Multi-Agent), and Daan Wierstra (Chief Scientist), plus CEO Charles Kantor.

Investors: Accel, UiPath ($35.2 million, according to Sifted), Bpifrance, Eric Schmidt, Xavier Niel, Amazon, FirstMark, Elaia Partners, Eurazeo, Yuri Milner, Aglaé Ventures (LVMH's Bernard Arnault), Creandum, Motier Ventures, Samsung, and Visionaries Club.

What's Next: H has already hired 25 engineers and scientists. The money will be used to expand its research team and pay for the massive computing power needed to develop its models, which the company claims is a first step toward its larger vision of full Artificial General Intelligence (AGI).

What: May Health is a clinical-stage medical device company developing a treatment for endocrine disorder polycystic ovary syndrome (PCOS).

Why: PCOS, which affects 10% of women, results from hormonal imbalance and is a leading cause of female infertility. It can also lead to increased risk for serious medical issues such as diabetes, cardiovascular disease, and strokes, as well as everyday problems such as irregular menstrual cycles, acne, hair loss, excessive hair growth, high blood pressure, and breathing difficulties during sleep.

Funding: €23 million
Who: The startup was originally founded in 2017 by Paris-based MD Start, a medical device incubator backed by Sofinnova Partners.

Investors: Bpifrance and Trill Impact Ventures led the round, which also included money from historical investor Sofinnova Partners, Avestria Ventures, and Kidron Capital Assets LP

What's Next: May Health now has offices in San Francisco as well. The company will use the money to continue clinical studies on its medical device.